BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.5 USD | -0.65% |
|
-1.95% | -16.51% |
ETFs positioned on BioMarin Pharmaceutical Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | -2.17% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - | |
| 0.83% | 14 M€ | -4.28% | ||
| 0.77% | 4 M€ | +20.15% | ||
| 0.47% | 253 M€ | +8.06% | ||
| 0.44% | 17 M€ | +6.60% | - | |
| 0.20% | 9 M€ | +15.45% | - | |
| 0.19% | 9 M€ | -.--% | - | |
| 0.09% | 744 M€ | +8.90% | ||
| 0.09% | 8 M€ | +4.60% | - | |
| 0.07% | 276 M€ | +11.40% | - | |
| 0.07% | 2,383 M€ | +12.58% | ||
| 0.06% | 1,487 M€ | +7.21% | - | |
| 0.06% | 9 M€ | +9.07% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 7 M€ | +0.11% | - | |
| 0.05% | 264 M€ | -.--% | - | |
| 0.05% | 187 M€ | +9.15% | - | |
| 0.05% | 477 M€ | +11.46% | ||
| 0.04% | 26 M€ | +16.85% | - | |
| 0.04% | 34 M€ | +11.93% | - | |
| 0.04% | 2,517 M€ | +12.09% | - | |
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 283 M€ | +19.00% | ||
| 0.03% | 206 M€ | -.--% | ||
| 0.03% | 607 M€ | +0.05% |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
15/05/2024
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
81.03
USD
Average target price
110
USD
Spread / Average Target
+35.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.51% | 15.39B | |
| -2.35% | 89.08B | |
| +2.76% | 40.9B | |
| -12.92% | 32.25B | |
| +54.69% | 25.14B | |
| -8.27% | 11.91B | |
| -42.60% | 11.89B | |
| -12.82% | 11.64B | |
| +7.34% | 9.03B | |
| -7.60% | 8.62B |
- Stock Market
- Equities
- BMRN Stock
- Funds and ETFs BioMarin Pharmaceutical Inc.
